Abstract: We found a 55% prevalence of TGs mainly heterozygous coagulation factor II, thrombin (FII)-
G20210A, Janus kinase 2 (JAK2)-
V617F, protein-
S, and antithrombin III deficiency with a high (76 9%) prevalence of venous UTEs, multiple vessels thrombosis, and recurrence rate among the TG versus non-TG subcohort.